+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

HER-2/neu evaluation in breast cancer are we there yet?

HER-2/neu evaluation in breast cancer are we there yet?

American Journal of Clinical Pathology 121 Suppl: S33

The HER-2/neu oncogene is located on chromosome 17q and encodes a transmembrane glycoprotein with intracellular tyrosine kinase activity. Several studies have shown an association of HER-2 gene amplification or protein overexpression with prognosis and predictor of therapeutic response. Most important, the presence of amplification or overexpression is the basis of eligibility for trastuzumab therapy. However, there are several methods of determining HER-2 status, each measuring a different aspect such as DNA content, gene copy number, protein expression, expression of RNA, and circulating HER-2 extracellular domain protein. There is no consensus with regard to the optimal test for HER-2 assessment. This review examines the various methods used in an attempt to define the most accurate and reliable test. The most widely used assays are immunohistochemical analysis and fluorescence in situ hybridization (FISH), which measure protein expression and gene amplification, respectively. Based on current data, FISH is the most accurate and reproducible test with a better correlation with prognosis and response to therapy.

Please choose payment method:

(PDF emailed within 1 workday: $29.90)

Accession: 049180349

Download citation: RISBibTeXText

PMID: 15298149

Related references

Incremental cancer detection using breast ultrasonography versus breast magnetic resonance imaging in the evaluation of newly diagnosed breast cancer patients. British Journal of Radiology 89(1065): 20160401, 2016

Evaluation of estrogen dependency of human breast cancers 2. clinical evaluation of tamoxifen in advanced primary and recurrent breast cancer. Hiroshima Journal of Medical Sciences 33(2): 163-166, 1984

Clinicopathological characteristics of breast cancer and trends in the management of breast cancer patients in Japan: Based on the Breast Cancer Registry of the Japanese Breast Cancer Society between 2004 and 2011. Breast Cancer 22(3): 235-244, 2016

The role of carcinoembryonic antigen in the postmastectomy follow-up of primary breast cancer and in the prognostic evaluation of disseminated breast cancer. Tumori 70(1): 57-59, 1984

Quality-of-life-adjusted evaluation of adjuvant therapies for operable breast cancer. The International Breast Cancer Study Group. Annals of Internal Medicine 114(8): 621-628, 1991

Evaluation of Breast Cancer Stem Cells and Intratumor Stemness Heterogeneity in Triple-negative Breast Cancer as Prognostic Factors. International Journal of Biological Sciences 12(12): 1568-1577, 2016

Evaluation of Breast Cancer Cases Diagnosed In the Breast Cancer Screening Program In the Near East University Hospital of North Cyprus. Journal of Breast Health 11(1): 22-25, 2015

A case-control evaluation of the effect of breast cancer screening in the United Kingdom trial of early detection of breast cancer. Journal of Epidemiology and Community Health 46(4): 362-364, 1992

Evaluation of breast cancer susceptibility loci on 2q35, 3p24, 17q23 and FGFR2 genes in Taiwanese women with breast cancer. Anticancer Research 32(2): 475-482, 2012

Evaluation of functional genetic variants for breast cancer risk: results from the Shanghai breast cancer study. American Journal of Epidemiology 173(10): 1159-1170, 2011

Evaluation of service screening for breast cancer by clinical breast examination using regional cancer registry data. Japanese Journal of Public Health 52(2): 128-136, 2005

Bilateral Salpingo-Oophorectomy Versus GnRH Analogue in the Adjuvant Treatment of Premenopausal Breast Cancer Patients: Cost-Effectiveness Evaluation of Breast Cancer Outcome, Ovarian Cancer Prevention and Treatment. Clinical Drug Investigation 37(11): 1093-1102, 2017

Contouring Guidelines for the Axillary Lymph Nodes for the Delivery of Radiation Therapy in Breast Cancer: Evaluation of the RTOG Breast Cancer Atlas. Breast Diseases: A Year Book Quarterly 27(2): 156-157, 2016

Contouring Guidelines for the Axillary Lymph Nodes for the Delivery of Radiation Therapy in Breast Cancer: Evaluation of the RTOG Breast Cancer Atlas. International Journal of Radiation Oncology Biology Physics 93(2): 257-265, 2015

Evaluation of radiotherapy in high-risk breast cancer patients: report from the Danish Breast Cancer Cooperative Group (DBCG 82) Trial. International Journal of Radiation Oncology Biology Physics 19(5): 1121-1124, 1990